Interestingly, mRNA transcriptomics from the GSE130588 study showed that treatment with dupilumab, an efficient biologic therapy for AD that inhibits signaling of both IL-4 and IL-13 [14,15], downregulated the transcriptional levels of the LGALS9 gene in lesion skins from AD patients compared to control skins (Figure 4h). This evidence concerns the gene LGALS9 and Alzheimer disease.